Navigation Links
The ETICS Project, Led by CYTOO in Collaboration With Cellectis bioresearch and the CEA, to Receive Euro 7.6 Million in Funding From OSEO

PARIS, Sept. 26, 2011 /PRNewswire/ -- CYTOO, a company that specializes in cell-based assays (Grenoble, France), has joined up with Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), and the CEA, the French Alternative Energies and Atomic Energy Commission, to develop new high-value cell-based assays for drug development and toxicology.

The project, named ETICS(1), will focus on the development of cell-based assays, which will be commercialized as kits, comprising cells genetically modified by Cellectis bioresearch and CYTOO's micropatterned supports. By controlling the expression, the architecture and the 2D and 3D environment of the cells, thus mimicking in vivo conditions of the tissue they derive from (liver, heart...), these assays will have much higher relevance to discover better and safer drugs.

OSEO, the French agency financing innovation, is providing euro 7.6 million in funding for the ETICS project for the next 5 years, including euro 4 million for CYTOO, euro 2.9 million for Cellectis bioresearch and euro 0.7 million for the CEA. This project could generate over euro 600 million for the consortium in ten years.

"The three partners of the ETICS project have complementary know-how and synergies in the key domains necessary for the success of such a project," said Francois Chatelain, Chairman and CEO of CYTOO.

"This funding will enable us to extend our product offering and to gain market share from our major North American competitors," stated Marc Le Bozec, Cellectis bioresearch CEO. "I would like to congratulate the ETICS partners and OSEO teams for the quality of work accomplished, which we believe will yield an important advancement in the development of new drugs."

About the "Industrial Strategic Innovation" Program from OSEO

The "Industrial Strategic Innovation" (ISI) program supports the emergence of European champions. It supports ambitious projects of collaborative innovation for the industry, carried by innovative medium-size companies (under 5.000 employees) and SMEs (under 250 employees). These projects hold a lot of promise: they aim at the commercialization of technological breakthrough products, and could not succeed without public support. The funding is usually comprised between euro 3 million and euro 10 million, in the form of subventions and reimbursable loans.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The genome customization products and services can be purchased online from Check the website for more information.

Follow Cellectis bioresearch on Twitter:

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at:

Follow Cellectis on Twitter:


CYTOO is a distinctive Life Sciences Systems/Tools enabling company that currently offers a disruptive solution that brings robustness, sensitivity and powerful quantification to cell-based assays and High Content Screening (HCS). The technology offers exquisite control over the cells' microenvironment, leading to normalized cell morphology and behavior. CYTOO is engaged in developing, manufacturing and commercializing innovative products to the Life Sciences research community (industry and academia). The Company has tailored a portfolio of innovative products using its proprietary cell adhesive micropattern technologies to target first its fast growing High Content Screening and Analysis segment within the large cell biology market


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

(1) ETICS stands for "Evolved Tissue Inspired Cell Systems"

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
5. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
8. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
9. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
10. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
11. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
Post Your Comments:
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... HILL, N.C. , Nov. 24, 2015  In ... research projects in an effort to quickly uncover new ... position. --> --> ... launch a market research project and ensure that all ... company and industry standards. Another major barrier to efficiently ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... In an ongoing Clinical Study conducted by an independent ... UV Angel is evaluating the efficacy of its product and its disinfection protocol. This ... beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical center ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent breast reconstruction ... incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my ... RECOVERY BRA for added comfort and support. The bra is easier to put ...
(Date:11/25/2015)... ... ... Since its launch in 2012, the Regenestem brand ( ... to patients with chronic degenerative medical conditions. Now, the U.S. Patent and Trademark ... Organizations are required to hold a registered trademark in order to make licensing ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... , ... In an article published November 12th by Obesity News ... or are not eligible for bariatric surgery. The article explains that candidates for weight ... 100 pounds overweight, or have a BMI of 35 and over with at least ...
Breaking Medicine News(10 mins):